Multiple myeloma historical perspective: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Multiple myeloma}} | {{Multiple myeloma}} | ||
{{CMG}} {{AE}}{{HL}} | {{CMG}} {{AE}}{{HL}} {{shyam}} | ||
==Overview== | ==Overview== | ||
| Line 7: | Line 7: | ||
==Historical Perspective== | ==Historical Perspective== | ||
*In '''1844''', Dr. Samuel Solly first | *In '''1844''', Dr. Samuel Solly reported the first case of multiple myeloma. He was a a surgeon working in St.Thomas hospital at London.<ref>Moehler T, Goldschmidt H. Multiple Myeloma. Springer Science & Business Media; 2011. https://books.google.com/books?isbn=3540857729 </ref><ref name="pmid18332230">{{cite journal| author=Kyle RA, Rajkumar SV| title=Multiple myeloma. | journal=Blood | year= 2008 | volume= 111 | issue= 6 | pages= 2962-72 | pmid=18332230 | doi=10.1182/blood-2007-10-078022 | pmc=2265446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18332230 }} </ref> Dr. Solly treated patients with rhubard and orange peel. | ||
*In '''1845''', abnormal urinary proteins were found to be associated with multiple myeloma. These were eventually coined as Bence Jones proteins. Dr. T. Watson treated patients with steel and quinine. | |||
*In '''1850''', Dr. Henry Bence Jones first described the Bence Jones protein and found it to be associated with multiple myeloma.<ref name="pmid21509678">{{cite journal| author=Kyle RA, Steensma DP| title=History of multiple myeloma. | journal=Recent Results Cancer Res | year= 2011 | volume= 183 | issue= | pages= 3-23 | pmid=21509678 | doi=10.1007/978-3-540-85772-3_1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21509678 }} </ref> | *In '''1850''', Dr. Henry Bence Jones first described the Bence Jones protein and found it to be associated with multiple myeloma.<ref name="pmid21509678">{{cite journal| author=Kyle RA, Steensma DP| title=History of multiple myeloma. | journal=Recent Results Cancer Res | year= 2011 | volume= 183 | issue= | pages= 3-23 | pmid=21509678 | doi=10.1007/978-3-540-85772-3_1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21509678 }} </ref> | ||
*In '''1895''', plasma cells were first described. It was later found that plasma cell proliferation was the cellular basis for multiple myeloma.<ref name="pmid18332230">{{cite journal| author=Kyle RA, Rajkumar SV| title=Multiple myeloma. | journal=Blood | year= 2008 | volume= 111 | issue= 6 | pages= 2962-72 | pmid=18332230 | doi=10.1182/blood-2007-10-078022 | pmc=2265446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18332230 }} </ref> | |||
*In '''1928''', the first large case series of multiple myeloma patients was reported.<ref name="pmid18332230">{{cite journal| author=Kyle RA, Rajkumar SV| title=Multiple myeloma. | journal=Blood | year= 2008 | volume= 111 | issue= 6 | pages= 2962-72 | pmid=18332230 | doi=10.1182/blood-2007-10-078022 | pmc=2265446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18332230 }} </ref> | |||
*In '''1939''', the monoclonal protein spike (M-spike) was described on protein electrophoresis. The M-spike was noted to be the gamma-globulin region.<ref name="pmid18332230">{{cite journal| author=Kyle RA, Rajkumar SV| title=Multiple myeloma. | journal=Blood | year= 2008 | volume= 111 | issue= 6 | pages= 2962-72 | pmid=18332230 | doi=10.1182/blood-2007-10-078022 | pmc=2265446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18332230 }} </ref> | |||
*In '''1947''', Dr. N. Alwall treated multiple myeloma patients with urethane. | |||
*In '''1956''', light chains were recognized to be a component of multiple myeloma.<ref name="pmid18332230">{{cite journal| author=Kyle RA, Rajkumar SV| title=Multiple myeloma. | journal=Blood | year= 2008 | volume= 111 | issue= 6 | pages= 2962-72 | pmid=18332230 | doi=10.1182/blood-2007-10-078022 | pmc=2265446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18332230 }} </ref> | |||
*In the '''1960s''', the chemotherapy agent [[melphalan]] was shown to improve overall survival in multiple myeloma.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | *In the '''1960s''', the chemotherapy agent [[melphalan]] was shown to improve overall survival in multiple myeloma.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | ||
*In '''1958''', Dr. N. Blokhin first used melphalan as a chemotherapy agent to treat multiple myeloma.<ref name="pmid18332230">{{cite journal| author=Kyle RA, Rajkumar SV| title=Multiple myeloma. | journal=Blood | year= 2008 | volume= 111 | issue= 6 | pages= 2962-72 | pmid=18332230 | doi=10.1182/blood-2007-10-078022 | pmc=2265446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18332230 }} </ref> | |||
*In '''1961''', the use of thalidomide was prohibited since it was found to be associated with birth defects.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | *In '''1961''', the use of thalidomide was prohibited since it was found to be associated with birth defects.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | ||
*In '''1962''', | |||
*In the 1990s, it was shown that high-dose therapy with autologous stem cell rescue led to improved patient outcomes.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | *In the 1990s, it was shown that high-dose therapy with autologous stem cell rescue led to improved patient outcomes.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | ||
*In '''1999''', Singhal and colleagues showed that thalidomide had a 32% response rate in a phase II clinical trial of relapsed/refractory multiple myeloma. | *In '''1999''', Singhal and colleagues showed that thalidomide had a 32% response rate in a phase II clinical trial of relapsed/refractory multiple myeloma. | ||
Revision as of 23:22, 14 July 2018
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma historical perspective On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma historical perspective |
|
Risk calculators and risk factors for Multiple myeloma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Shyam Patel [3]
Overview
Multiple myeloma was first discovered by Dr. Samuel Solly, a surgeon working in St.Thomas hospital in London in 1844.[1]The Bence Jones protein was first discovered by Dr. Henry Bence Jones and found to be associated with multiple myeloma in 1850; And the term “Bence Jones protein” was first used by Fleischer in 1880. PMID:29194778
Historical Perspective
- In 1844, Dr. Samuel Solly reported the first case of multiple myeloma. He was a a surgeon working in St.Thomas hospital at London.[2][3] Dr. Solly treated patients with rhubard and orange peel.
- In 1845, abnormal urinary proteins were found to be associated with multiple myeloma. These were eventually coined as Bence Jones proteins. Dr. T. Watson treated patients with steel and quinine.
- In 1850, Dr. Henry Bence Jones first described the Bence Jones protein and found it to be associated with multiple myeloma.[4]
- In 1895, plasma cells were first described. It was later found that plasma cell proliferation was the cellular basis for multiple myeloma.[3]
- In 1928, the first large case series of multiple myeloma patients was reported.[3]
- In 1939, the monoclonal protein spike (M-spike) was described on protein electrophoresis. The M-spike was noted to be the gamma-globulin region.[3]
- In 1947, Dr. N. Alwall treated multiple myeloma patients with urethane.
- In 1956, light chains were recognized to be a component of multiple myeloma.[3]
- In the 1960s, the chemotherapy agent melphalan was shown to improve overall survival in multiple myeloma.[5]
- In 1958, Dr. N. Blokhin first used melphalan as a chemotherapy agent to treat multiple myeloma.[3]
- In 1961, the use of thalidomide was prohibited since it was found to be associated with birth defects.[5]
- In 1962,
- In the 1990s, it was shown that high-dose therapy with autologous stem cell rescue led to improved patient outcomes.[5]
- In 1999, Singhal and colleagues showed that thalidomide had a 32% response rate in a phase II clinical trial of relapsed/refractory multiple myeloma.
- In 2003, the proteasome inhibitor bortezomib was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma.
- In 2014, the International Myeloma Working Group (IMWG) revised the diagnostic criteria for active multiple myeloma to include bone marrow plasma cell burden > 60%, serum free light chain ratio > 100, and greater than 1 bony lesion on MRI.
References
- ↑ Moehler T, Goldschmidt H. Multiple Myeloma. Springer Science & Business Media; 2011. https://books.google.com/books?isbn=3540857729
- ↑ Moehler T, Goldschmidt H. Multiple Myeloma. Springer Science & Business Media; 2011. https://books.google.com/books?isbn=3540857729
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Kyle RA, Rajkumar SV (2008). "Multiple myeloma". Blood. 111 (6): 2962–72. doi:10.1182/blood-2007-10-078022. PMC 2265446. PMID 18332230.
- ↑ Kyle RA, Steensma DP (2011). "History of multiple myeloma". Recent Results Cancer Res. 183: 3–23. doi:10.1007/978-3-540-85772-3_1. PMID 21509678.
- ↑ 5.0 5.1 5.2 Hong J, Lee JH (2016). "Recent advances in multiple myeloma: a Korean perspective". Korean J Intern Med. 31 (5): 820–34. doi:10.3904/kjim.2015.408. PMC 5016289. PMID 27604794.